Limit of detection of bacterial contaminant in living bacterial vaccine

Gina M. M. Elamry1, 2 and Marwa M. S. Khedr

Central Laboratory For Evaluation Veterinary Biologics, Agricultural Research Center, Giza

ARTICLE INFO

Keywords
Bacterial contamination
Bacterial vaccine
Kappa index

ABSTRACT

A total number of 30 vaccine vials including 3 batches of 3 different types of live bacterial poultry vaccines (Mycoplasma red vaccine, Mycoplasma yellow vaccine and non-colored Mycoplasma vaccine) were experimentally contaminated with 1, 5, 10 CFU of Escherichia coli reference strain (ATCC25992) /dose then subjected for sterility testing as referenced in world organization of animal health(OIE). The sterility is defined as the absence of viable microorganisms, includes viruses. It should be achieved by the use of aseptic techniques and validated sterilization methods, including heating, filtration, chemical treatments and irradiation that fit the intended purpose. Further dilution was carried out of vaccines showing negative results. Kappa index in different contamination levels in all tested vaccines after dilution was ranged between high Kappa index and almost total. In this study, it concluded that the applied testing method is appropriate for testing sterility of living bacterial poultry vaccines and it is fit to use.

1. INTRODUCTION

Bacterial infections of poultry are a worldwide important factor in terms of the economic losses and public health. The control of these diseases depends on high-cost sanitary measures and medical treatment. The protection effect of bacterial vaccines depends on the immune response of the host towards different antigenic components of the bacteria (Nagwa and Zeinab, 2020). The sterility is defined as the absence of viable microorganisms, includes viruses. It should be achieved by the use of aseptic techniques and validated sterilization methods, including heating, filtration, chemical treatments and irradiation that fit the intended purpose. Free contamination is defined as the absence of specified viable microorganisms. Adequate assurance of sterility and freedom from contaminating microorganisms can only be achieved by proper control of the primary materials used and their subsequent processing. Tests on intermediate products are necessary throughout the production process to check that this control has been achieved (OIE, 2019).

In the validation process was estimated by repeatability and reproducibility of the test method (Annex -1, 2017) aiming to secure that the test methods are good enough to qualify the tested vaccines. Large economic values as well as considerable health, safety and environmental issues are involved, much more emphasis must be paid to the validation of the test methods. The frequency of the tested method should also be considered when determining the extent of validation. The total consequences of wrong results are of course larger for methods in extensive use than for test methods used occasionally (Excel kontrol, en 2008 and Excel control version 2.1 (2008). This study aimed to assess the validity of the used method for testing the sterility of live bacterial poultry vaccines.

2. MATERIAL AND METHODS

2.1. Samples
Thirty vaccine vials including 3 batches (3 vials of each batch) of live attenuated bacterial poultry vaccines including Mycoplasma (red colored) vaccine, Mycoplasma (yellow) vaccine and Mycoplasma (non-colored) vaccine were kindly obtained from bacterial sterility department, Central Laboratory for Evaluation of Veterinary Biologics, Abbassia, Cairo.

2.2. Spike
Escherichia coli reference strain (ATCC25992) was kindly obtained from the Reference Strain Bank, Central Laboratory for Evaluation of Veterinary Biologics (CLEVB) Abbassia, Cairo.

2.3. Preparation of the inoculum
Three beads of E.coli strains were enriched in 3 tubes of peptone water and incubated at 37°C overnight. These broth cultures were tenfold serially diluted to be used in spiking the tested vaccines at different 3 levels of contamination according to Reynolds (2005) as follow:

1st level reveals 1 CFU/dose in vaccine vial.
2nd level reveals 5 CFU/ dose in vaccine vial.
3rd level reveals 10CFU/ dose in vaccine vial.

2.4. Testing method
The used sterility testing method was carried out following up the directions of OIE (2019) where each vaccine vial was dissolved in 2 ml sterile distilled water then inoculated to thiglycolate broth produced by Sigma aldrich Company, fluid thiglycolate+0.5 beef extract produced by Sigma aldrich Company, Soyabean digest medium produced by Sigma aldrich Company in a ratio 1:15, followed by experimentally contamination with a level of bacterial
concentration then incubated at 35°C and 25°C for 14 days and examined for turbidity and subcultures at 3rd to 11th day by transferring 0.1 ml from turbid sample to: Brain heart infusion agar produced by Sigma Aldrich Company Tryptose Soya agar produced by Sigma Aldrich Company and Mycoplasma agar produced by Oxoid Company for typical growth or atypical growth for Mycoplasma

2.5. Media and reagent performance
According to ISO / 11133-1 (2014), the used media in this study were tested before inoculation to validate their efficacy by measuring the productivity and selectivity.

2.5. Criteria of validation
The validation study depends on different parameters and tools to evaluate if the method is fit to use in check vaccine sterility or not. The parameters used were selectivity, trueness, sensitivity, specificity, concordance, repeatability and reproducibility according to the requirement of ISO 16140-6 (2019) taking in consideration that:

Trueness = \((a + d)/n \times 100\)

Sensitivity = \(a/(a + b) \times 100\)

Specificity = \(d/(c + d) \times 100\)

Concordance Index Kappa = \(\frac{(a + d)}{(n-1)}\) \(\times \frac{100}{(a + b + c + d)}\)

Where: a= Number of positive agreements. b= number of false negatives. c= Number of false positives. d= Number of negative agreements. n= Total number of results.

### Table 1 Concordance-Index kappa according to ISO/TC 34/SC 9/WG3 N027

| Kappa index | Value |
|-------------|-------|
| None        | <0.1  |
| Low         | >0.1-0.4 |
| Distinct    | >0.4-0.6 |
| High        | >0.6-0.8 |
| Almost total| >0.8-1 |

3. RESULTS

The contamination was able to be detected in all spiked batches of Mycoplasma (red colored) vaccine at all levels of contamination (level 1 “1 CFU/dose”, level 2 “5 CFU/dose” and level 3 “10 CFU/dose”) (Table 2).

### Table 2 Limits of Detection (LOD) for Mycoplasma (red colored) vaccine

| Levels of contamination | Tested vaccines | Batch 1 | Batch 2 | Batch 3 |
|-------------------------|----------------|---------|---------|---------|
| Level 1 (1CFU/vaccine vial) | +ve | +ve | +ve |
| Level 2 (5CFU/vaccine vial) | +ve | +ve | +ve |
| Level 3 (10CFU/vaccine vial) | +ve | +ve | +ve |

Table 3 showed that all spiked batches of Mycoplasma (yellow)vaccine showed the contamination could not be detected at 1 out of 3 batches of vaccine vials in level 1 (1 CFU/dose) and while it could be detected at level 2 (5 CFU/dose) and level 3 (10 CFU/dose) in all tested batches.

### Table 3 Limits of Detection (LOD) for Mycoplasma (yellow)vaccine

| Levels of contamination | Tested vaccines | Batch 1 | Batch 2 | Batch 3 |
|-------------------------|----------------|---------|---------|---------|
| Level 1 (1CFU/vaccine vial) | +ve | +ve | -ve |
| Level 2 (5CFU/vaccine vial) | +ve | +ve | +ve |
| Level 3 (10CFU/vaccine vial) | +ve | +ve | +ve |

Table 4 showed that in all spiked batches of Mycoplasma (non-colored) vaccine, the contamination could not be detected at 1 out of 3 batches of vaccine vials with level 1 (1 CFU/dose) and while it could be detected at level 2 (5 CFU/dose) and level 3 (10 CFU/vaccine vial) in all batches.

### Table 4 Limits of Detection (LOD) for Mycoplasma (non-colored) vaccine

| Levels of contamination | Tested vaccines | Batch 1 | Batch 2 | Batch 3 |
|-------------------------|----------------|---------|---------|---------|
| Level 1 (1CFU/vaccine vial) | +ve | +ve | -ve |
| Level 2 (5CFU/vaccine vial) | +ve | +ve | +ve |
| Level 3 (10CFU/vaccine vial) | +ve | +ve | +ve |

The obtained results revealed that the Mycoplasma (red colored) vaccine; the specificity, sensitivity, trueness and concordance where 100, 100, 100 and 1 consequently reflecting the validity of the used method in this vaccine type, while in colored and non-colored Mycoplasma vaccines at level 1 contamination the specificity; sensitivity, trueness and concordance were 100, 83.3, 50.88, 66.7 and 0.88,0.57 consequently as shown in table (5). These results were considered of low validity for the used method in these types of vaccines.

Dilution of tested vaccine at level 1 contamination indicated that the Mycoplasma (red colored) vaccine the contamination could not be detected at second dilution (10ml) while could be detected in the other 2 dilutions, while in the Mycoplasma (yellow)vaccine and Mycoplasma (non-colored) vaccine the contamination was detected in second dilution (10 ml) as shown in Table (6).

The results of tested vaccines after dilution showed that in case of Mycoplasma (red colored) vaccine; the specificity, sensitivity, trueness and concordance were 100,100,100 and 1 consequently while in case of Mycoplasma (yellow)vaccine and Mycoplasma (non-colored) vaccine the specificity, sensitivity, trueness and concordance where 100,80.5,90.5 and 0.9 consequently as tabulated in Table (7).

### Table 5 Criteria of validation study for tested vaccines at level 1 of contamination (1 CFU/dose)

| Tested vaccine | Specificity | Sensitivity | Trueness | Concordance Value | Kappa Index |
|----------------|-------------|-------------|---------|------------------|-------------|
| Mycoplasma (red colored) | 100 | 100 | 100 | 100 | Almost total |
| Mycoplasma (yellow) | 83.3 | 83.3 | 83.3 | 83.3 | Almost total |
| Mycoplasma (non-colored) | 50 | 50 | 50 | 50 | Distinct |

### Table 6 Limits of Detection (LOD) for diluted tested vaccines

| Tested vaccine | Detection of contamination with vaccine dilutions |
|----------------|-----------------------------------------------|
|                | 5ml | 10ml | 20ml |
| Mycoplasma (red colored) | +ve | -ve | +ve |
| Mycoplasma (yellow) | +ve | +ve | +ve |
| Mycoplasma (non-colored) | -ve | +ve | +ve |
Table 7 Criteria of validation study for all contamination levels in examined living bacterial vaccines after dilution

| Tested vaccine                        | Specificity | Sensitivity | Trueness | Concordance value | Kappa Index | Criteria of validation |
|---------------------------------------|-------------|-------------|----------|-------------------|-------------|------------------------|
| Mycoplasma (red colored) vaccine      | 100         | 100         | 100      | 1                 | Almost total|                        |
| Mycoplasma (yellow) vaccine           | 100         | 100         | 100      | 1                 | Almost total|                        |
| Mycoplasma (non-colored) vaccine      | 100         | 80.5        | 90.5     | 0.91              | Almost total|                        |

4. DISCUSSION

It was stated that sterility testing is a process that confirm the presence or absence of extraneous viable contaminating microorganisms in biologics (Lee, 1990) who described a detailed sterility investigation that included the identification of the contaminant, reviews of documents, training records, gowning practices, environmental monitoring records, lab procedures and other critical controls as well as validity for any method used to detect bacterial contamination (OIE, 2019).

In this study, the obtained results revealed that the used method for detection of bacterial contamination of poultry bacterial vaccines; is fit to fulfill such purpose was in agreement with that obtained by Kamboh et al., (2009) who found that lower bacterial contamination in poultry vaccines.

All the obtained result shown in table(1),(2),(3),(4),(5),(6) and (7) was agreed with the result obtained by Hanan M. Ibrahim, et al. (2019) who found that lower bacterial contamination in poultry vaccines.

All results through the present study indicate that the used method of bacterial contamination of bacterial vaccines; is fit to fulfill such purpose. As the result agreed with (CRF, 2015).

These findings secure that the used test method is good enough to qualify the tested vaccines (Excel kontrol, en 2008 and Excel kontrol version 2.1 (2008)).

5. REFERENCES

1. Annex 1. 2017. Manufacture of sterile Medical Products, European Commission December 2017.
2. CODE OF FEDERAL REGULATION"CRF".2015.Title 9. Animals and Animal products
3. Excel kontrol (en) 2008. New control x-chart for a new control chart (Excelcontrol@gmail.com).
4. Excel kontrol version 2.1. 2008. Rules for out of control
5. Hanan M. Ibrahim; Hanan, A. Ahmed; Nouhran, Nagy; Gina M. Mohamed, Shafai, S.M. and Aly, A.M(2019). Detection limits of live attenuated poultry viral vaccine testing method for detection of bacterial contamination. Journal of Applied Veterinary Sciences, 4(1): 1 -4.
6. ISO 16140-6(2019) Microbiology of the food chain — Method validation — Part 6: Protocol for the validation of alternative (proprietary) methods for microbiological confirmation and typing procedures Published by the Office of the Federal Register. National Archives and Records Administration
7. ISO/TC 34/SC 9/WG3 N027(2016)Horizontal methods in the field of microbiological analysis of the food chain from primary production stage to food and animal feed product
8. ISO/TS 11133-1. 2014. General guideline on quality assurance for preparation of culture media in the laboratory.
9. Kamboh, A.A., Arain, Z.M., Rajput, N. and Abro, S.H. (2009). A study on bacterial contamination of poultry vaccines. Journal of Agriculture and Social Science, 5: 46-48
10. Lee, J.Y.( 1990). Investigating Sterility Test Failure.journal of Pharmaceutical Technology, 38-43.
11. Nagwa,S.R. and Zeinab,M.S.(2020). Bacterial vaccine in poultry. Bulletin National Research Center, 44, 15 (2020). https://doi.org/10.1186/s42269-019-0260-1
12. OIE( 2019). Infection disease in OIE quality standard and guidelines for veterinary laboratories (world organization for health).
13. Reynolds,J. (2005). American Society for Microbiology, 6, 26 (1), 265-274.